GPX4 and cancer: Our demonstration that sensitivity to GPX4 inhibitors is correlated with NUAK2 expression across numerous cancer cell types (Fig. 7a) suggests that NUAK2 expression may be a potent predictor of vulnerability to GPX4 inhibition.